Amino Acids and Exercise in FSHD

Официальное название

Amino Acid Supplementation and Physical Exercise in Facioscapulohumeral Muscular Dystrophy: Effects on Body Composition and Physical Efficiency in a Model of Muscular Disease

Обзор

This study evaluates whether amino acid supplementation, combined with a structured diet and exercise program, improves body composition (increased muscle mass and reduced fat mass) and physical performance in individuals with facioscapulohumeral muscular dystrophy (FSHD). The study also compares responses to the intervention between individuals with FSHD and healthy individuals matched for age and sex.

Подробное описание

Background and Rationale: Facioscapulohumeral muscular dystrophy (FSHD) is a rare disease (≈1:15,000-1:20,000) characterized by progressive muscle weakness, primarily affecting the face, shoulders, and upper body. The condition is associated with reduced strength, aerobic capacity, walking ability, and increased fatigue, leading to impaired quality of life. In the absence of a curative treatment, conservative strategies are essential. Exercise has demonstrated beneficial effects; however, the combined impact of exercise and amino acid supplementation-known to stimulate protein synthesis-has not been investigated in individuals with FSHD and may help counteract muscle loss. Objectives: The primary objective is to evaluate the effects of amino acid supplementation on body composition and physical performance in individuals with FSHD undergoing a standardized nutritional and exercise program.

The secondary objective is to compare these effects with those observed in healthy individuals matched for age and sex. Expected Outcomes: Amino acid supplementation is expected to result in greater improvements in lean mass, fat mass, aerobic fitness, muscle strength, walking performance, and daily physical activity compared to placebo. Improvements are expected in both groups; however, individuals with FSHD may exhibit smaller gains due to altered protein synthesis.

Study Population: The study will enroll 24 adults with genetically confirmed FSHD, aged 18-50 years, with mild to moderate disease severity and preserved walking ability. Participants will be recruited from the University of Pavia and the Italian National FSHD Registry. A control group of 24 healthy individuals, matched for age and sex, will be recruited through institutional channels.

Study Design: This is a randomized, double-blind, placebo-controlled crossover study. The intervention duration is 15 months per participant. Due to the rarity of the disease, total study completion is anticipated within approximately 36 months. Participants with FSHD will complete two 6-month intervention phases separated by a 3-month washout period, receiving both amino acid supplementation (essential amino acid mixture) and placebo (maltodextrins) in random order. Assessments will be conducted at baseline and at the end of each intervention phase. Healthy control participants will complete a single 6-month intervention phase. Intervention and Assessments: Participants will undergo evaluations including body composition, resting metabolic rate, handgrip strength, gait analysis, cardiopulmonary fitness (VO₂max), and daily physical activity measured via accelerometry. The intervention consists of a personalized dietary plan and a home-based exercise program including moderate-intensity aerobic training and resistance exercises targeting major muscle groups. Supplementation includes two daily doses of either amino acids or placebo, administered under blinded conditions. Risks and Safety: The study involves minimal risk. Potential risks are primarily related to minor injuries associated with home-based exercise. Risk mitigation strategies include participant instruction, monitoring, and the prescription of appropriate exercise protocols.

Вмешательства

• Пищевая добавка Essential Amino Acids Supplementation intervention
  Use of a balanced essential amino acids mixture to counteract muscle deterioration in FSHD
• Поведенческое Exercise
  Tailored exercise
• Поведенческое Diet
  Tailored balanced diet
• Другое Placebo Control
  Placebo, diet and exercise in FSHD

Первичные конечные точки

• Change in fat mass in FSHD [Срок оценки: From enrollment to the end of treatment at 15 months]
• Change in fat-free mass in FSHD [Срок оценки: From enrollment to the end of treatment at 15 months]
• Change in aerobic capacity in FSHD [Срок оценки: From enrollment to the end of treatment at 15 months]
• Change in muscle strength in FSHD [Срок оценки: From enrollment to the end of treatment at 15 months]
• Change in walking performance in FSHD [Срок оценки: From enrollment to the end of treatment at 15 months]

Критерии участия

Критерии включения

• Subjects of both sexes with a diagnosis of FSHD, confirmed by genetic testing.
• Age between 18 and 50 years.
• Belonging to clinical category A among the four defined in the Comprehensive Clinical Evaluation Form. These patients present the most characteristic signs of the disease: muscle weakness of the facial and scapular girdle.
• Clinical score ranging from 2 to 5.
• Preserved ability to walk at the time of enrollment.
• Absence of central or peripheral nervous system involvement based on neurological history and physical examination.
• Absence of scoliosis, limb contractures, and tendon retractions.

Критерии исключения

• Use of beta-blocker medications;
• Psychological or psychiatric disorders;
• Musculoskeletal injuries that impair the ability to perform physical exercise;
• Recent medication adjustment, use of drugs that may affect fatigue, or use of fatigue-stimulating agents (e.g., Modafinil, amantadine);
• Ongoing participation in another clinical investigation involving a medical device or drug, or participation in such a study completed less than 30 days prior;
• Pregnant or breastfeeding women;
• Patients unable to understand the purpose and conditions of the study and unable to provide informed consent;
• Presence of additional diseases that may interfere with measurements;
• Patients deprived of liberty or under legal guardianship.

Healthy participants will be age- and sex-matched adults without neuromuscular disease:

• no chronic disease;
• no neuromuscular disorders;
• Same age range.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Да

Дизайн исследования

Распределение

Рандомизированное

Модель

Перекрёстный дизайн

Маскирование

Тройное слепое

Основная цель

Лечение

Центры проведения

Италия · 1 центр

• Criams Sport Medicine Centre — Voghera

Публикации

• Verceles AC, Serra M, Davis D, Alon G, Wells CL, Parker E, Sorkin J, Bhatti W, Terrin ML. Combining exercise, protein supplementation and electric stimulation to mitigate muscle wasting and improve outcomes for survivors of critical illness-The ExPrES study. Heart Lung. 2023 Mar-Apr;58:229-235. doi: 10.1016/j.hrtlng.2022.11.013. Epub 2022 Dec 5. PMID 36473808
• Vera KA, McConville M, Kyba M, Keller-Ross ML. Sarcopenic Obesity in Facioscapulohumeral Muscular Dystrophy. Front Physiol. 2020 Aug 12;11:1008. doi: 10.3389/fphys.2020.01008. eCollection 2020. PMID 32903446
• Schipper K, Bakker M, Abma T. Fatigue in facioscapulohumeral muscular dystrophy: a qualitative study of people's experiences. Disabil Rehabil. 2017 Sep;39(18):1840-1846. doi: 10.1080/09638288.2016.1212109. Epub 2016 Oct 20. PMID 27762634
• Rijken NH, van Engelen BG, de Rooy JW, Weerdesteyn V, Geurts AC. Gait propulsion in patients with facioscapulohumeral muscular dystrophy and ankle plantarflexor weakness. Gait Posture. 2015 Feb;41(2):476-81. doi: 10.1016/j.gaitpost.2014.11.013. Epub 2014 Dec 2. PMID 25687333
• Ricci G, Ruggiero L, Vercelli L, Sera F, Nikolic A, Govi M, Mele F, Daolio J, Angelini C, Antonini G, Berardinelli A, Bucci E, Cao M, D'Amico MC, D'Angelo G, Di Muzio A, Filosto M, Maggi L, Moggio M, Mongini T, Morandi L, Pegoraro E, Rodolico C, Santoro L, Siciliano G, Tomelleri G, Villa L, Tupler R. A novel clinical tool to classify facioscapulohumeral muscular dystrophy phenotypes. J Neurol. 201 PMID 27126453
• Prieur-Blanc N, Cotinat M, Vansteenkiste S, de Bovis Milhe V, Viton JM, Attarian S, Bensoussan L. Fitness and walking outcomes following aerobic and lower extremity strength training in facioscapulohumeral dystrophy: a case series. Int J Rehabil Res. 2024 Mar 1;47(1):41-45. doi: 10.1097/MRR.0000000000000614. Epub 2024 Jan 6. PMID 38323889
• Negro M, Perna S, Spadaccini D, Castelli L, Calanni L, Barbero M, Cescon C, Rondanelli M, D'Antona G. Effects of 12 Weeks of Essential Amino Acids (EAA)-Based Multi-Ingredient Nutritional Supplementation on Muscle Mass, Muscle Strength, Muscle Power and Fatigue in Healthy Elderly Subjects: A Randomized Controlled Double-Blind Study. J Nutr Health Aging. 2019;23(5):414-424. doi: 10.1007/s12603-019- PMID 31021358
• Morse CI, Bostock EL, Twiss HM, Kapp LH, Orme P, Jacques MF. The cardiorespiratory response and physiological determinants of the assisted 6-minute handbike cycle test in adult males with muscular dystrophy. Muscle Nerve. 2018 Sep;58(3):427-433. doi: 10.1002/mus.26146. Epub 2018 May 17. PMID 29669172

Идентификаторы

NCT: NCT07543016 · FSH_2025, v.3.0, 07/04/2026

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗